Novo Nordisk A/S (Novo Nordisk A/S) Accumulated Depreciation

: $-6,968 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Novo Nordisk A/S's quarterly accumulated depreciation stayed the same from Jun. 2023 ($0 Mil) to Sep. 2023 ($0 Mil) but then increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($-6,968 Mil).

Novo Nordisk A/S's annual accumulated depreciation increased from Dec. 2021 ($-6,158 Mil) to Dec. 2022 ($-6,373 Mil) and increased from Dec. 2022 ($-6,373 Mil) to Dec. 2023 ($-6,968 Mil).

Novo Nordisk A/S Accumulated Depreciation Historical Data

The historical data trend for Novo Nordisk A/S's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

-5,037.86

-5,954.97

-6,157.88

-6,372.72

-6,967.58

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated Depreciation																-6,372.72	-	-	-	-6,967.58

Novo Nordisk A/S Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Novo Nordisk A/S Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.